Drugs / Tetuzumab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07152366 Comparator | Apr 2025 → May 2027 expected | disease of orbital part of eye adnexa | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetuzumab | “Tetuzumab (IBI311) is a fully human monoclonal insulin-like growth factor-1 receptor inhibitory antibody.” NCT07152366 ↗ |
| Known as | IBI311 | “Tetuzumab (IBI311) is a fully human monoclonal insulin-like growth factor-1 receptor inhibitory antibody.” NCT07152366 ↗ |
| Action | Inhibit | “can block the binding of IGF-1 and IGF-2 to IGF-1R” NCT07152366 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal insulin-like growth factor-1 receptor inhibitory antibody” NCT07152366 ↗ |
| Target | IGF1R | “binding activity against IGF-1R positive cells” NCT07152366 ↗ |